Innovative Therapies for Hepatitis Delta Virus and Other Serious Diseases
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and serious diseases with high unmet medical needs and no approved therapies.
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $98.9 million in Cash, Cash
- Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events - Lambda reduced risk of hospitalization or emergency room visits by 51% (primary endpoint)
President and CEO David A. Cory resigns from the company effective immediately Dr. David Apelian named Interim CEO PALO ALTO, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Eiger BioPharmaceuticals, Inc. (“Eiger” or “the company”) (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on